Rocket Pharmaceuticals (RCKT) Touches 5-Year High on Positive Gene Expression; Also, Prices Upsized Common Stock Offering
Rocket Pharmaceuticals reports promising Phase 1 data from its gene therapy in heart disease. RCKT shares skyrocketed, reaching a five-year high of $63.94. The pharmaceutical firm upsizes its public offering of 4.6 million of its common stock, valued at $260 million. Shares of Rocket Pharmaceuticals, Inc. (RCKT) rallied to their 5-years high after the company […]
